1 가톨릭대학교 의과대학 내과, 2 순환기 내과, 강남성모병원 연구배경: B-type natriuretic peptide(BNP)는 심인성 및 다른 쇼크 상태를 포함하는 심혈관 질환에서 사망을 예측하는 좋은 인자 중의 하나로 알려져 있다. 그러나, 급성호흡곤란증후군환자에서 이런 관계가 잘 알려져 있지 않는 바, 저자들은 BNP가 급성호흡곤란증후군 환자에서 사망을 예측할 수 있는 지를 연구하였다. 방 법: 본 연구는 전향적 관찰로 시행되었다. 급성호흡곤란증후군으로 진단된 환자들에게 심초음파 검사를 시행한 후, 좌심실 구획률이 50% 미만이거나 확장성 심부전 양상을 보인 환자들을 제외하였다. 2003년 12월부터 2006년 2월까지 총 47명의 환자가 채택되었다. 등록된 환자들은 24시간 내로 BNP를 포함한 여러 검사실 수치를 얻었으며, APACHE (Acute Physiology and Chronic Health Evaluation) II 점수를 구하였다. 결 과: BNP와 APACHE II 점수 평균값은 생존자군과 사망자군에서 유의한 차의를 보였다(BNP: 219.5±57.7 pg/mL vs 492.3±88.8 pg/mL; p=0.013, APACHE II 점수: 17.4±1.6 vs 23.1±1.3, p=0.009). BNP 는 혈중 크레아티닌 수치와 양의 상관 관계를 보였으나(r=0.374, p=0.01), 좌심실 구획률과는 유의한 관계가 없었다. Receiver operating characteristic 곡선상, BNP 수치를 585 pg/mL로 잡았을 때 사망을 예측하는데 있어서 94%의 특이도를 보였으며, APACHE II 점수의 경우에는 15.5를 기준으로 하였을 때 87%의 민감도를 보였다. 이 두 요소를 결합하여 '아파치II 점수+11×logBNP' 수치를 계산하여 기준점을 46.14로 했을 경우, 사망 예측에 있어서 민감도 63%, 특이도 82%의 결과를 얻을 수 있었다. 결 론: 좌심실 기능 부전을 보이지 않는 급성호흡곤란증후군 환자에서 BNP 수치는 생존자군과 사망자군에서 유의한 차이를 보였으며 사망을 예측할 수 있었다. 향후 급성호흡곤란증후군 환자에 있어서 BNP와 관련된 연구가 더 필요하다고 생각된다. (Tuberc Respir Dis 2007; 62: 389-397)
INTRODUCTION
Among patients with congestive heart failure (CHF), B-type natriuretic peptide (BNP) concentrations reflect left ventricular end-diastolic pressure, left ventricular ejection fraction, and New York Heart Association heart failure class [1] [2] [3] [4] [5] . Assay for BNP has shown comparable accuracy in diagnosing, monitoring and establishing prognosis in patients with heart failure [6] [7] [8] [9] . Although there were some reports that BNP can be elevated in patients with ARDS 10, 11 , little is known about the correlation between BNP and mortality in patients with ARDS. Some articles about BNP in patients with shock or respiratory failure were published, but the enrolled patients were not 100% ARDS patients [12] [13] [14] . Moreover, many of enrolled patients showed low ejection fraction, and this definitely affected the BNP concentration. We performed this study to see if BNP concentrations were elevated in patients with ARDS who had normal ejection fraction and evaluate the relationship between BNP and other variables. We also investigated if BNP and other variables could show difference between 
METHODS

Study Design
This was a prospective observational study. The median BNP concentrations among those dying were significantly higher than those surviving (p = 0.013). physiology and chronic health evaluation (APACHE) II scores among surviving patients vs. those dying during the study. The median APACHE II scores among those dying were significantly higher than those surviving (p = 0.009).
High Positive End-Expiratory Pressures (PEEP)
was defined as more than 15 cmH 2 O. The patients, researchers, physicians, and echocardiographers were blinded to the BNP concentrations.
Statistical Analysis
Independent samples T test was done to compare means of continuous variables. Chi-square test was used for analysis of categorical variables.
Correlations between each variable were evaluated by bivariate analysis with Pearson correlation.
Receiver operating characteristic (ROC) curves for BNP and APACHE II score were constructed to predict mortality. All statistical analyses were performed with SPSS software (Chicago, IL, USA). 
RESULTS
Clinical characteristics and mortality
Correlation
BNP concentration was correlated with serum creatinine level (r = 0.374, p = 0.010), but not with EF, age, PaO2, FiO2, PaO2/FiO2, CRP, and APACHE II score. APACHE II score was correlated with PaO2/FiO2 (r = -0.292, p = 0.047), Cr (r = 0.375, p = 0.009) ( Table 3) .
BNP concentration
In total enrolled patients, mean BNP concentration was 393 ± 63 pg/mL, and 66% of patients showed elevated BNP level (>100 pg/mL). We examined percentage of patients who are BNP > 100 pg/mL and mean BNP concentration between variable medical conditions( Table 4 ). These conditions can be causes of raised plasma BNP level 18 . Sepsis patients showed significantly increased percentage of BNP elevation, but mean BNP didn't differ significantly. In other conditions, although higher percentages were seen, p values were more than 0.05.
Area Under Curve = 0.678 Area Under Curve = 0.710 Figure   3 ). In order to combine these two factors, we used log-transformed BNP values. 'APACHE II + 11×logBNP' showed the best result of AUC (0.747).
Using the threshold value for 46.14, sensitivity was 63%, and specificity was 82% (Figure 4 ). Area Under Curve = 0.747 given in Table 5 .
DISCUSSION
BNP can be elevated not only in CHF patients but also other critically ill patients 12, 19 . Little is known in ARDS patients. Maeder and colleagues 10 reported one case of ARDS patient who showed marked elevation of BNP in spite of normal ejection fraction. Although there are some articles about BNP in respiratory failure patients 13, 14 , none of them were about only ARDS patients. We wanted to evaluate the relationship between BNP and mortality in ARDS patients, and also to exclude the effect of LV dysfunction on BNP. So, we enrolled patients who met the diagnostic criteria of ARDS, and ruled out any patients who had less than 50% of ejection fraction and/or any features of diastolic dysfunction. This can explain the relatively small number of patients in this study in spite of long study period.
BNP concentrations among those who died were higher than those who survived in shock patients 12 .
Although APACHE II score is well known predictor of mortality in critically ill patients, there was no significant difference in APACHE II score between two groups in that study. In a Jefic D et al's study, mean BNP concentrations did not differ between the survivors and nonsurvivors in respiratory failure patients, and mean APACHE II scores were higher in nonsurvivors than in survivors 13 . In our study, not only BNP concentrations but also APACHE II scores are elevated significantly in patients who died. Our study is unique in that we enrolled only ARDS patients and ruled out LV dysfunction patients. This may be the reason of the different result compared to previous two similar studies.
What we tried to show was BNP could be elevated in ARDS patients without the effect of LV dysfunction, and this elevation could be related to the mortality. We clearly showed that BNP concentrations and APACHE II scores were elevated significantly in nonsurvivors. BNP is useful biomarkers for the diagnosis of HF.
However, BNP might be raised to different degrees in critical illness and various pulmonary diseases. In these situations, BNP may also serve as markers of severity and prognosis 18 . ARDS is one of these diseases, and we showed BNP > 585 pg/mL has a high specificity for the prediction of mortality.
APACHE II score is well known predictor of mortality in critical illness patients. BNP also seems to be the predictor of mortality. APACHE II score and BNP were not correlated significantly in critically ill patients 19 . In our study, the result was also same. We hypothesized that BNP could reflect certain conditions which APACHE II score couldn't cover. So, we combined there two markers hoping they could produce synergistic result in predicting mortality. BNP concentrations showed wide variation compared to APCHE II score, so log BNP was used to correct this problem. The concept of log BNP was adapted from previous published study 12 . Although there was no reference in combination of these two scores, we could prove 'APACHE II + 11×logBNP' was better than BNP or APACHE II in predicting mortality.
It is well known that the BNP is elevated in patients with low ejection fraction. However, in our study, there was no correlation between BNP 
